Two patients suffering from dystrophic epidermolysis bullosa have experienced first substantial improvement after treatment by KB103 gene therapy.
DEB is a disease affecting skin health and leading to complicated wounds with a long time of healing.
KB103 aims to help patients with DEB by insertion of the gene COL7. Virus vector HSV-1 with COL7 gene is injected into a wound to integrate the gene with human cells. Additional activity of COL7 produces protein named collagen VII, which substantially mitigates symptoms of the disease.
In the first month of the clinical trials, two patients have seen the healing of wounds enriched with the new gene over time of 2 weeks – in contrast to untreated wounds, which were open for over 10 weeks.
The clinical trial of KB103 therapy will be continued March 2019 with a total number of 6 participants.
More: “Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103”, Krystal Biotech.